Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-09-14 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司关于委任董事会薪酬委员会成员的公告
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the appointment of a member to the company's board remuneration committee. It specifically mentions the appointment of an independent non-executive director to the board's remuneration committee and the effective date of the appointment. There is no financial data, no report attached or referenced, and the content relates to board/management changes. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming this classification.
2022-09-14 Chinese
港股公告：董事名单及其角色与职能
Board/Management Information Classification · 100% confidence The document lists the members of the board of directors and their roles and committee memberships. It includes details about executive, non-executive, and independent non-executive directors, as well as their committee assignments. There is no financial data, no mention of a report being attached or published, no voting results, no legal proceedings, no capital changes, and no earnings information. The content is focused on board composition and governance structure. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short but contains substantive information about board members, not just an announcement or notice, so it is not RPA or RNS.
2022-09-14 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, as required under the Hong Kong Stock Exchange Listing Rules (Main Board and GEM). It details share issuance under an employee share scheme, share counts before and after issuance, and compliance confirmations by the company's executive director and CEO. The document is a regulatory disclosure of share capital changes rather than a full financial report or announcement of a report. It fits the definition of a Share Issue/Capital Change announcement, as it reports on new share issuance and related capital changes.
2022-09-13 Chinese
百济神州有限公司自愿披露关于在2022年欧洲肿瘤内科学会上展示百泽安（替雷利珠单抗注射液）最新临床数据的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. about the latest clinical data presented at the 2022 European Society for Medical Oncology (ESMO) conference regarding their drug, Tislelizumab. It includes detailed clinical trial results, study descriptions, and risk disclosures related to the drug development and regulatory approval process. The document does not contain financial statements or comprehensive financial performance data. It is not an earnings release or annual/interim report. It is also not a regulatory filing or certification. The content focuses on clinical trial data disclosure and risk factors, typical of a regulatory announcement about clinical progress rather than a financial or governance report. Given the length (3281 characters) and content, it is a regulatory announcement about clinical data disclosure, best classified under Regulatory Filings (RNS).
2022-09-12 Chinese
中国国际金融股份有限公司、高盛高华证券有限责任公司关于百济神州有限公司2022年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022年半年度持续督导跟踪报告" which translates to "2022 Semi-Annual Continuous Supervision Follow-up Report." It is issued by joint sponsors (保荐机构) of a listed company 百济神州有限公司 (BeiGene Ltd.) and covers the period from January 1, 2022 to June 30, 2022. The content includes detailed supervisory activities, findings, risk factors, financial data for the half-year period, and compliance with regulatory requirements. It contains substantive financial data and analysis for the half-year period, including revenue, net profit, cash flow, and other financial indicators. The document is a comprehensive report for a period shorter than a full fiscal year and is not merely an announcement or certification. It is not a full annual report (10-K), but a half-year report with detailed financial and operational information. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-09-07 Chinese
港股公告：证券变动月报表
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipt issuer under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, share options, and confirmations related to share issuance and compliance with listing requirements. The document is structured as a regulatory compliance report submitted to the Hong Kong Stock Exchange, focusing on share capital changes and share issuance confirmations. It does not contain financial statements, earnings data, management discussion, or other report types such as annual or interim reports. It is not a simple announcement of a report but a detailed regulatory filing about share capital changes. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is 4798 characters, which is substantial and contains detailed tabular data and confirmations, supporting this classification.
2022-09-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.